LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

About Study 19

BRCAm Sub-analysis

Patients with BRCAm platinum-sensitive relapsed ovarian cancer experience the greatest clinical benefit with Lynparza.2,3

A pre-planned subgroup retrospective analysis by BRCAm status identified patients with BRCAm ovarian cancer (n=136, 51%) as the subgroup that derived the greatest clinical benefit from Lynparza maintenance monotherapy.3

Retrospective analysis by BRCAm status identified patients with BRCAm ovarian cancer
Retrospective analysis by BRCAm status identified patients with BRCAm ovarian cancer

Adapted with permission from Ledermann.2